News

The transaction was finalized on the 30 April 2012 and the other terms related to the transaction are confidential. Chesapeake CEO Mike Cheetham said, "This acquisition will enable

The new ZAR300m ($38.3m) facility is in compliance with the international Pharmaceutical Inspection Convention and Pharmaceutical Co-operation Scheme Standards adopted by the South African Medicines Control Council. Adcock

Upon the completion of the sale, which is expected in the second quarter of 2012, the facility’s employees will become the employees of Perryman. Accellent president and CEO

The R&D center will focus on the development of science-based nutrition products for maternal and child nutrition and diabetes care. Abbott Nutrition Global R&D and Scientific Affairs divisional

The deal is intended for the production of hyperimmune colostrum for Immuron’s products, including its Travelan treatment for travellers’ diarrhoea. Immuron chief executive officer Joe Baini said, "As

The company has received FDA regulatory clearance for the randomized, multicenter, open-label, active-controlled trial of F-627. Generon CEO Yu-Liang Huang said, "This is the first innovative biologic drug

After the review of the supplemental new drug application (sNDA), which was submitted in June 2011, the FDA has announced the decision. Sunovion executive vice president and chief

The US District Court for the District of Delaware has found both the patents in a suit brought against Mylan Pharmaceuticals are valid. Genentech, OSI, (a US affiliate

Nevirapine 200mg tablets are AB rated to Viramune, which is marketed by Boehringer Ingelheim. The non-nucleoside reverse transcriptase inhibitor (NNRTI) is indicated for the treatment of HIV-1 infection